Cytosen Therapeutics

View All

Amgen reveals price; Bardy raises $35.5M; Kiadis to Acquire CytoSen; Insitro lands a deal

Amgen reveals the price of EVENITY Amgen has set the price of its newly launched Osteoporosis drug Romosozumab (Evenity). Worth USD 21,900 per annum or USD 1,825 a month, the bone-building drug was approved by the FDA recently for the treatment of Osteoporosis in postmenopausal women and now will be available i...

Find More

COMMERCIAL AND OTHERS

Cytosen Therapeutics and KBI Biopharma pair up to manufacture NK cells and Nanoparticles  CytoSen Therapeutics and KBI Biopharma paired up to manufacture therapeutic Natural Killer Cell by using a closed system manufacturing process. According to the initial collaboration, KBI will be subjected to manufactur...

Find More